In fact, a retrospective study revealed that tocilizumab-treated COVID-19 patients had a higher tendency for fungal infections and increased mortality.[82] Other studies have indicated that tocilizumab treatment in COVID-19 patients elevates the risk of CAPA, with 1 prospective study noting a 100% mortality rate post-Aspergillus infection in such patients.[83–86] While some studies suggest an increased risk of CAPA development in COVID-19 patients treated with anti-IL-6 drugs, more research is required to understand their immunological impact on CAPA. This evidence concerns the gene IL6 and episodic ataxia type 2.